Crystalline composition containing escitalopram

a technology of crystalline composition and escitalopram, which is applied in the field of antidepressant drugs, can solve the problems of poor flow properties, poor cohesiveness or poor flow properties of active substances, and complex and expensive equipment and technical skill, and achieves the effects of improving the efficiency of escitalopram and improving the effect of escitalopram absorption and absorption

Inactive Publication Date: 2005-09-08
H LUNDBECK AS
View PDF8 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028] A fifth aspect of the invention is to provide a method for manufacture of large crystalline particles of escitalopram oxalate comprising reduction of the amount of hydroxyl containing impurities in a solution of escitalopram

Problems solved by technology

However, in many cases the particle size of the active substance is small, the active substance is cohesive or has poor flow properties.
Wet granulation as well as melt granulation are energy intensive unit operations requiring complicated and expensive equipment as well as technical skill.
The process used for the preparation of citalopram hydrobromide results in a product with a very sma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline composition containing escitalopram

Examples

Experimental program
Comparison scheme
Effect test

example 1

Scavenging of Hydroxyl Containing Impurity by Succinic Anhydride

[0082] A mixture of R— and S-Citalopram (55.5 g) containing 0.6% of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile is dissolved in dry toluene (145.0 g). Succinic anhydride (0.5 g) is added to the solution and the mixture is stirred at 45° C. (120 minutes). Water (230 ml) and aqueous ammonia (25% by weight) (3 ml) is added (pH=10.5-11.0). The phases are separated and the toluene phase is washed with water (3×120 ml). The toluene phase is evaporated and the yield is 53.0 g (95%). The product contains 0.06% of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile.

example 2

Production Scale Crystallisation of Escitalopram Oxalate

[0083] A large number of batches of crude escitalopram oxalate have been recrystallised in production scale according to the procedure described below. The batches comprises: [0084] a) Escitalopram prepared by acidic ring-closure of the R-form of the diol precursor as described in WO03 / 000672 followed by scavenging of hydroxyl containing impurity by a production scale version of the process described in example 1 followed by separation of racemic citalopram and escitalopram as described in WO03 / 000672. These batches contain Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile, typically in the range of 0.05% (w / w) relative to escitalopram. These batches are referred to as R-diol batches. [0085] b) Escitalopram prepared by ring-closure of the S-form of the diol precursor via an activated ester under alkaline conditions as described in U.S. Pat. No. 4,943,590. These batches do not contain Z-4-(4-dimet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention discloses crystalline particles of escitalopram oxalate which either have a broad particle size distribution or comprise at least 0.01% (w/w) of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile, said particles being suitable for use in direct compression. Furthermore, the invention discloses a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as methods for manufacture of such crystalline particles of escitalopram oxalate Finally, the invention provides a method for reduction of the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram.

Description

[0001] Under 35 U.S.C. § 119(e), this application claims the benefit of prior U.S Provisional Application No. 60 / 550,909, filed Mar. 5, 2004, which is incorporated herein by reference in its entirety.[0002] The present invention relates to crystalline preparations of the oxalate salt of the compound escitalopram (INN-name), which is the S-enantiomer of the well-known antidepressant drug citalopram, i.e. (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate. BACKGROUND OF THE INVENTION [0003] Citalopram is a well-known antidepressant drug that has the following structure: It is a selective, centrally active serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, accordingly having antidepressant activities. [0004] Citalopram was first disclosed in DE 2,657,013, corresponding to U.S. Pat. No. 4,136,193. This patent publication describes the preparation of citalopram by one method and outlines a further method, which may be used for prep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/14A61K31/343C07D307/87
CPCA61K31/343A61K9/2054C07D307/87
Inventor JENSEN, KIM B.HUMBLE, RIKKE E.LILJEGREN, KENCHRISTENSEN, TROELS V.
Owner H LUNDBECK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap